Dedeepya Pharma

India
Pharmaceutical manufacturing and supply of affordable medicines for acute and chronic conditions in India.

About Dedeepya Pharma

Dedeepya Pharma is a Healthcare company based in India. Pharmaceutical manufacturing and supply of affordable medicines for acute and chronic conditions in India. Its Indian entity Dedeepya Pharma Private Limited reported revenue of β‚Ή167 Cr. Dedeepya Pharma offers products and services including Ceftriaxone and Meropenem. Its focus areas include Pharmaceuticals, Drug Manufacturing, Specialty Pharmaceuticals and Medical Supplies.

Company details

Dedeepya Pharma is recognized as an emerging Indian pharmaceutical company that focuses on sustaining life and promoting healthcare through the provision of high-quality, effective, and affordable medicines for a broad spectrum of conditions. Products are thoroughly assessed for safety, quality, and efficacy to ensure they can be utilized with confidence across all stages of life. The company strives towards innovation in medicine to meet unmet needs in therapy areas while upholding values like commitment, passion, teamwork, and quality. Accessibility to these formulations is emphasized to contribute to better health outcomes in India.

  • Headquarters India
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Website dedeepyapharma.in
  • Legal Name Dedeepya Pharma Pvt. Ltd
  • Date of Incorporation 11 Dec, 2014
  • Jurisdiction Hyderabad, Telangana, India
Key Metrics
  • Annual Revenue
    ₹167 Cr

    FY 2024 · +86% YoY

  • Net Profit
    ₹5.15 Cr

    FY 2024 · 3% margin

  • EBITDA
    ₹8.96 Cr

    FY 2024 · 5% margin

Products & Services of Dedeepya Pharma

Dedeepya Pharma offers a comprehensive portfolio of products and services, including Ceftriaxone and Meropenem.

Ceftriaxone
Antibiotics

This product is manufactured as an injectable for treating bacterial infections and is supplied for use in critically ill patients.

Meropenem
Antimicrobials

This medication is provided in injection form for addressing severe infections and is included in the portfolio of supportive treatments.

Board of directors of Dedeepya Pharma Private Limited (Dedeepya Pharma)

Dedeepya Pharma Private Limited is the primary company behind Dedeepya Pharma. The board of Dedeepya Pharma Private Limited currently have 5 directors; the longest-serving is Mahidhar Reddy Dasari, appointed in 2014.

DirectorDesignationAppointedTenureEntity
Mahidhar Reddy Dasari
DIN 07031133
Whole-time director11 Dec 201411 yrs 11 moDedeepya Pharma Private Limited
Manjula Dasari
DIN 07031139
Whole-time director11 Dec 201411 yrs 11 moDedeepya Pharma Private Limited
Varun Reddy Dasari
DIN 07031141
Managing Director11 Dec 201411 yrs 11 moDedeepya Pharma Private Limited
Preeti Reddy Dasari
DIN 07253245
Director05 Aug 201511 yrs 3 moDedeepya Pharma Private Limited
Niharika Reddy Kondakindi
DIN 08637098
Director30 Sep 20242 yrs 1 moDedeepya Pharma Private Limited

Financials of Dedeepya Pharma

Figures of Dedeepya Pharma Private Limited, the primary company behind Dedeepya Pharma, for FY 2024. Revenue was ₹167 Cr (+86% year on year). Net profit was ₹5.15 Cr (3% margin). EBITDA was ₹8.96 Cr (5% margin). Revenue has grown at a compounded annual rate of +75% over three years and +39% over five years.

  • ₹167 CrRevenue · FY 2024 · +86% YoY
  • ₹5.15 CrNet profit · 3% margin
  • ₹8.96 CrEBITDA · 5% margin
  • ₹1.50 CrPaid-up capital
  • +75%Revenue CAGR, 3 years
  • +39%Revenue CAGR, 5 years

Balance sheet, profit and loss, cash flow and ratios of Dedeepya Pharma Private Limited are on its company page.

Premium access

Detailed financial statements for Dedeepya Pharma

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about Dedeepya Pharma

Dedeepya Pharma is headquartered in India.

The primary company behind Dedeepya Pharma, Dedeepya Pharma Private Limited, reported revenue of β‚Ή167 Cr for FY 2024, up 86% year on year.

Dedeepya Pharma is recognized as an emerging Indian pharmaceutical company that focuses on sustaining life and promoting healthcare through the provision of high-quality, effective, and affordable medicines for a broad spectrum of conditions. Products are thoroughly assessed for safety, quality, and efficacy to ensure they can be utilized with confidence across all stages of life. The company strives towards innovation in medicine to meet unmet needs in therapy areas while upholding values like commitment, passion, teamwork, and quality. Accessibility to these formulations is emphasized to contribute to better health outcomes in India.

Dedeepya Pharma offers Ceftriaxone and Meropenem.

Dedeepya Pharma operates through Dedeepya Pharma Private Limited.

The legal entities of Dedeepya Pharma currently have 5 directors, including Mahidhar Reddy Dasari, Manjula Dasari, Varun Reddy Dasari and others.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available